Market Place
Sourcing Support
Darzalex Subcutaneous Regimen Benefits Newly Diagnosed Myeloma
03 Jun 2025 //
GLOBENEWSWIRE
J&J’s PARP inhibitors Combo Shows Benefit in HRR+ mCSPC
03 Jun 2025 //
PR NEWSWIRE
Johnson & Johnson`s Trispecific Antibody Shows Promise in Myeloma
03 Jun 2025 //
PR NEWSWIRE
Carvykti Infusion Leads to Lasting Remissions in Myeloma
03 Jun 2025 //
PR NEWSWIRE
J&J shares survival data on KLK2 bispecific in prostate cancer
03 Jun 2025 //
FIERCE BIOTECH
J&J Show Early Anti-Tumor Effect Of Pasritamig In Prostate Cancer
01 Jun 2025 //
PR NEWSWIRE
Johnson & Johnson Investor Call on Q2 Results
28 May 2025 //
BUSINESSWIRE
FDA Advisors Back Darzalex as Treatment for Early Myeloma
21 May 2025 //
FIERCE PHARMA
Johnson & Johnson at Bernstein`s 41st Annual Conference
21 May 2025 //
BUSINESSWIRE
FDA Panel Backs Darzalex Faspro for High-Risk Myeloma
20 May 2025 //
PR NEWSWIRE
J&J trials IVL-first Strategy in Women with Blocked coronaries
20 May 2025 //
FIERCE BIOTECH
J&J, Pfizer and Roche face FDA questions over data applicability
17 May 2025 //
FIERCE PHARMA
Johnson & Johnson at Goldman Sachs 46th Annual Health Conference
14 May 2025 //
BUSINESSWIRE
Stylus outlines next-gen gene editing mission with $85M in hand
13 May 2025 //
FIERCE BIOTECH
Icotrokinra shows skin clearance in scalp and genital psoriasis
09 May 2025 //
PR NEWSWIRE
Johnson & Johnson Boosts Global Support for Nursing workforce
08 May 2025 //
BUSINESSWIRE
EU Commission Approved Tremfya for Crohn`s disease in adults
07 May 2025 //
GLOBENEWSWIRE
J&J gene therapy fails ph. 3 rare eye disease trial
06 May 2025 //
FIERCE BIOTECH
Tremfya is first Drug for subcutaneous induced Ulcerative Colitis
05 May 2025 //
PR NEWSWIRE
J&J tries to reopen lawsuit against expert witness in talc cases
05 May 2025 //
FIERCE PHARMA
J&J-backed HistoSonics explores sale at $2.5 billion valuation
02 May 2025 //
REUTERS
US FDA approves J&J`s immune disorder drug
01 May 2025 //
PRESS RELEASE
Johnson & Johnson at Bernstein`s 41st Annual Conference
28 Apr 2025 //
BUSINESSWIRE
J&J’s TAR-200 monotherapy achieves 80% disease-free survival
28 Apr 2025 //
GLOBENEWSIRE
J&J puts ImmunityBio on defense mode in bladder cancer
27 Apr 2025 //
FIERCE PHARMA
Next-gen pulsed field ablation comes to the fore at HRS
25 Apr 2025 //
FIERCE BIOTECH
Tremfya approved by European Commission for ulcerative colitis
25 Apr 2025 //
GLOBENEWSWIRE
J&J & Lilly Concealed Breast Cancer Risks in Antipsychotics Drug
24 Apr 2025 //
PR NEWSWIRE
Compremium AG Appoints Dr. Kolaleh Eskandanian to Lead Pediatrics
23 Apr 2025 //
ACCESSWIRE
J&J Unveils Bladder Cancer Data at AUA, Potential Game Changer
21 Apr 2025 //
PR NEWSWIRE
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
17 Apr 2025 //
GLOBENEWSWIRE
Johnson & Johnson at 2025 RBC Capital Markets Healthcare Conf
16 Apr 2025 //
BUSINESSWIRE
Johnson & Johnson CEO warns US tariffs may disrupt drug supply
16 Apr 2025 //
REUTERS
Johnson & Johnson Reports Q1 2025 Results
15 Apr 2025 //
BUSINESSWIRE
Johnson & Johnson Raises Quarterly Dividend by 4.8% for 63rd Year
15 Apr 2025 //
BUSINESSWIRE
J&J Reports First Cases With Ottava Surgical Robot
14 Apr 2025 //
FIERCE BIOTECH
Icotrokinra: 75% of adolescents with psoriasis achieve clear skin
10 Apr 2025 //
PR NEWSWIRE
ValoTx Appoints Marcella Origgi as CEO
09 Apr 2025 //
GLOBENEWSWIRE
EU Commission OKs DARZALEX-based Regimen for New Myeloma
09 Apr 2025 //
PR NEWSWIRE
J&J Links Fcrn Blocker To Sustained Benefits As Fda Ruling Nears
08 Apr 2025 //
FIERCE BIOTECH
J&J`S Shockwave To Test Javelin Lithotripsy In Coronary Arteries
08 Apr 2025 //
FIERCE BIOTECH
Novo’S Wegovy, J&J’S Tremfya Led March Tv Ad Spending Totals
08 Apr 2025 //
FIERCE PHARMA
Johnson & Johnson shows long-term disease control in gMG
08 Apr 2025 //
GLOBENEWSWIRE
J&J showcases long-term data on nipocalimab in Myasthenia Gravis
08 Apr 2025 //
PR NEWSWIRE
EU Commission OKs RYBREVANT for advanced EGFR-mutated lung cancer
07 Apr 2025 //
GLOBENEWSWIRE
Johnson & Johnson at BofA Securities 2025 Healthcare Conference
07 Apr 2025 //
BUSINESSWIRE
EU Commission OKs Rybrevant with Enhanze for EGFR Lung Cancer
07 Apr 2025 //
PR NEWSWIRE
Tremfya reduces signs, symptoms, and damage in psoriatic arthritis
04 Apr 2025 //
PR NEWSWIRE
J & J Announces Expected Closing Date for Intra-Cellular Acquisition
01 Apr 2025 //
BUSINESSWIRE
US judge rejects J&J`s $10 billion baby powder settlement
01 Apr 2025 //
REUTERS
Johnson & Johnson to Defeat Talc Claims in Tort System
31 Mar 2025 //
BUSINESSWIRE
J&J unit ordered to pay $1.64 B in HIV drug marketing case
29 Mar 2025 //
REUTERS
Tremfya® gets CHMP approval for Crohn’s Disease treatment
28 Mar 2025 //
GLOBENEWSWIRE
Rybrevanta plus Lazcluze outperforms osimertinib in lung cancer
27 Mar 2025 //
PR NEWSWIRE
RYBREVANT plus LAZCLUZE® demonstrates overall survival benefit
26 Mar 2025 //
GLOBENEWSWIRE
Nipocalimab data at AAN 2025 show positive Phase 3 results
26 Mar 2025 //
PR NEWSWIRE
J&J touts $55B in planned US investments over 4 years
22 Mar 2025 //
BUSINESSWIRE
J&J`s Tremfya picks up key FDA nod in Crohn`s disease
21 Mar 2025 //
FIERCE PHARMA
Rybrevant, Lazcluze Show Strong Data In 1L EGFR Lung Cancer
20 Mar 2025 //
PR NEWSWIRE
Nipocalimab granted FDA Breakthrough and Fast Track designations
18 Mar 2025 //
PR NEWSWIRE
